Cagrilintide 5mg vial

Amylin analogue

What is Cagrilintide?

Last updated: 29 October 2026

A long-acting acylated amylin analogue (AM833), studied on its own and in combination with GLP-1 compounds.

Amylin analogueInvestigational · not approved
Class
Amylin receptor agonist
Also known as
AM833
Type
Acylated amylin analogue
Research stage
Clinical trials; not an approved medicine

01 · Classification

What it is

Amylin is a hormone released alongside insulin by pancreatic beta cells. Cagrilintide is a modified, long-acting version of amylin, engineered with a fatty-acid chain so it lasts much longer than the native hormone in study models.

It is a non-selective agonist that acts at both amylin receptors and the related calcitonin receptor.

02 · Mechanisms

What has been studied

  • Amylin receptors (AMY1–3): receptor complexes formed by the calcitonin receptor and RAMP proteins, studied for satiety signalling in the hindbrain.
  • Calcitonin receptor: cagrilintide also activates this receptor, which is part of why it is described as a dual amylin/calcitonin agonist.
  • Combination research: much of the published work pairs it with a GLP-1 agonist to study complementary pathways.

03 · Evidence

Where the research is

Phase 2 and phase 3 trials have been published or are under way. It is not approved by the FDA as a standalone product.

04 · Primary sources

Read the literature

Search the primary research record directly rather than relying on summaries, including this one.

Research use only

Supplied strictly for laboratory and educational research. Not a drug, not for human or veterinary use, and not evaluated by the FDA. This overview is not medical advice and gives no dosing or administration guidance.

← All research overviews